DUBLIN--(BUSINESS WIRE)--The "North America Immunodiagnostic Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product, Clinical Indication and End User" report has been added to ResearchAndMarkets.com's offering.
The North America immunodiagnostic market is expected to reach US$ 15,040.40 million in 2028 from US$ 9,188.19 million in 2021. The market is estimated to grow with a CAGR of 7.3% from 2022 to 2028.
The market growth is mainly attributed to factors such as the increasing prevalence of infectious diseases and the rising use of point-of-care immunodiagnostics. However, the inadequate reimbursement scenario hinders the market growth.
Research and development (R&D) are an essential part of pharmaceutical and biopharmaceutical businesses. R&D enables them to develop new products for various diagnostic applications with significant medical and commercial potential. Due to the increasing prevalence of infectious diseases, companies are investing and generating huge revenues, which further helps them in expansion activities.
Thermo Fisher Scientific Inc. witnessed a 48% increase in sales in its Specialty Diagnostics segment (sub-segmented into clinical diagnostics, immunodiagnostics, microbiology, transplant diagnostics, and healthcare market channels) in 2020. Its segmental revenue further increased in 2021 due to higher demand, particularly for immunodiagnostics products used in the treatment of COVID-19. Additionally, in May 2021, PerkinElmer agreed to acquire Immunodiagnostic Systems (IDS), a UK-based in-vitro diagnostics company, for ~US$ 155 million. With this acquisition, PerkinElmer aims to expand its overall diagnostics business and immunodiagnostics division.
Based on product, the immunodiagnostic market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. The chemiluminescence immunoassay (CLIA) is further categorized into vitamin D assay, HIV detection, HIV Ag/Ab combo assay, and others. The enzyme-linked immunosorbent assays (ELISA) segment held the largest market share in 2021.
Based on clinical indication, the immunodiagnostic market is segmented into infectious diseases, hepatitis+HIV, gastrointestinal, metabolic diseases, endocrinology, and others. The infectious disease segment is further divided into COVID-19, Tuberculosis, Lyme, Infection Management, Zika, Treponema, TORCH, Measles & Mumps, VZV, and EBV. The infectious diseases segment held the largest share of the market in 2021.
Based on end user, the immunodiagnostic market is segmented into hospitals, clinics, diagnostics laboratories, academic & research institutes, and others. The hospitals segment held the largest share of the market in 2021.
Market Dynamics
Market Drivers
- Increasing Prevalence of Infectious Diseases
- Increasing Use of Point-of-Care Immunodiagnostics
Market Restraints
- Inadequate Reimbursement Scenario
Market Opportunities
- Rising Focus On R&D Investment and Expansion by Key Players
Future Trends
- Technological Advancements in The Field of Immunodiagnostics
Key Topics Covered:
1. Introduction
2. North America Immunodiagnostics Market - Key Takeaways
3. Research Methodology
4. Immunodiagnostics Market- Market Landscape
5. Immunodiagnostics Market - Key Market Dynamics
6. Immunodiagnostics Market- North America Analysis
7. Immunodiagnostics Market Analysis and Forecasts To 2028 - By Product
8. Immunodiagnostics Market Analysis and Forecasts To 2028 - By Clinical Indication
9. Immunodiagnostics Market Analysis and Forecasts To 2028 - By End User
10. North America Immunodiagnostics Market - Country Analysis
11. North America: Impact Assessment of COVID-19 Pandemic
12. Immunodiagnostics Market -Industry Landscape
13. Company Profiles
14. Appendix
Companies Mentioned
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- DiaSorin S.p.A.
- Danaher Corp
- Thermo Fisher Scientific Inc
- Siemens Healthineers AG
- PerkinElmer Inc.
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- bioMerieux SA
For more information about this report visit https://www.researchandmarkets.com/r/kpebyq
